Atul Pande (Director) sold ~$108K of Immunovant
Planned saleWant the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
IMVT · NASDAQ · Biological Products, (No Diagnostic Substances)
Immunovant (IMVT) · oqro.io/stocks/IMVT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$31.77−0.75 (−2.31%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Including 5 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only
Atul Pande (Director) sold ~$108K of Immunovant
Planned saleTraded Nov 11, 2026 · largest single transaction ~$25K
Nov 11, 20263,000 · @ $8.43
DetailsOfficial recordNov 11, 20263,000
DetailsOfficial recordAtul Pande (Director) plans to sell ~$214K of Immunovant
Planned, from payTiago Girao (Chief Financial Officer) sold ~$188K of Immunovant
Automatic saleJay S Stout (Chief Technology Officer) sold ~$75K of Immunovant
Automatic saleMelanie Gloria (Chief Operating Officer) sold ~$72K of Immunovant
Automatic saleJay S Stout (Chief Technology Officer) sold ~$71K of Immunovant
Automatic saleJay S Stout (Chief Technology Officer) sold ~$51K of Immunovant
Automatic saleTuyl Christopher Van (Chief Legal Officer) sold ~$43K of Immunovant
Automatic saleEric Venker (Chief Executive Officer) sold ~$120K of Immunovant
Automatic saleTraded Oct 1, 2026 · largest single transaction ~$1.33M
Oct 1, 202692K · @ $14.46
DetailsOfficial recordInsider filing
Traded Oct 1 · filed 5 days later
Not classified as an open-market trade.
Tuyl Christopher Van (Chief Legal Officer) sold ~$103K of Immunovant
Automatic saleJay S Stout (Chief Technology Officer) sold ~$51K of Immunovant
Automatic saleMichael Geffner (Chief Medical Officer) sold ~$43K of Immunovant
Automatic saleJay S Stout (Chief Technology Officer) sold ~$26K of Immunovant
Automatic saleMichael Geffner (Chief Medical Officer) sold ~$20K of Immunovant
Automatic saleMichael Geffner (Chief Medical Officer) sold ~$35K of Immunovant
Automatic saleJay S Stout (Chief Technology Officer) sold ~$28K of Immunovant
Automatic salePeter Salzmann (Chief Executive Officer) sold ~$124K of Immunovant
Automatic saleEva Renee Barnett (Chief Financial Officer) sold ~$45K of Immunovant
Automatic salePeter Salzmann (Chief Executive Officer) sold ~$365K of Immunovant
Automatic saleEva Renee Barnett (Chief Financial Officer) sold ~$91K of Immunovant
Automatic saleEva Renee Barnett (Chief Financial Officer) sold ~$53K of Immunovant
Automatic saleMichael Geffner (Chief Medical Officer) sold ~$80K of Immunovant
Automatic saleJay S Stout (Chief Technology Officer) sold ~$65K of Immunovant
Automatic saleAndrew J. Fromkin (Director) sold ~$129K of Immunovant
Planned saleAndrew J. Fromkin (Director) sold ~$28K of Immunovant
Planned salePeter Salzmann (Chief Executive Officer) sold ~$322K of Immunovant
Automatic saleEva Renee Barnett (Chief Financial Officer) sold ~$59K of Immunovant
Automatic saleWilliam L. Macias (Chief Medical Officer) sold ~$43K of Immunovant
Automatic saleMichael Geffner (Chief Medical Officer) sold ~$63K of Immunovant
Automatic saleJay S Stout (Chief Technology Officer) sold ~$52K of Immunovant
Automatic salePeter Salzmann (Chief Executive Officer) sold ~$199K of Immunovant
Automatic saleEva Renee Barnett (Chief Financial Officer) sold ~$52K of Immunovant
Automatic saleWilliam L. Macias (Chief Medical Officer) sold ~$45K of Immunovant
Automatic salePeter Salzmann (Chief Executive Officer) sold ~$10K of Immunovant
Automatic saleEva Renee Barnett (Chief Financial Officer) sold ~$2.6K of Immunovant
Automatic sale0 open-market purchases and 9 open-market sales by insiders of IMVT between Jan 7, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 9, 2026. The data provider lists the next release for Feb 4, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 9, 2026 | 2 sales | None | 1 sale |
| Aug 6, 2026 | None | None | None |
| May 20, 2026 | None | None | None |
| Feb 6, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies